Ambien News and Research

RSS

NovaDel receives Issue Notification from USPTO for oral spray

NovaDel Pharma Inc., today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

16 Dec 2009

Computerized alerts induce clinicians to prescribe comparable generic equivalents

Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs. A study in the August issue of Journal of General Internal Medicine found that when clinicians received computerized alerts, which compared medication brands, they changed 23.3 percent of prescriptions for four heavily marketed sleep medications to comparable generic equivalents.

10 Nov 2009

USPTO issues Notice of Allowance to NovaDel Pharma

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology.

6 Nov 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009

Meda launches EDLUAR in the U.S.

Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.

9 Sep 2009

Nighttime acid reflux symptoms impair sleep quality

There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.

1 Sep 2009

MRRI research study to investigate how zolpidem might restore consciousness for patients in the vegetative state

Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore consciousness for patients in the vegetative state.

31 Aug 2009

Sharp increase in use of prescription sleep aids by young adults

Use of prescription sleep aids nearly tripled among 18- to 24-year-olds between 1998 and 2006, according to a study released today by the Healthcare business of Thomson Reuters.

19 Jan 2009

Save money wih generics

Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.

10 Dec 2008

WSJ examines drugmakers' use of 'unbranded product advertising' to promote disease awareness, treatment options

The Wall Street Journal on Friday examined "unbranded product advertising" for brand-name drugs, which allow drugmakers to drive television viewers to Web sites promoting drugs without the requirement of listing the products' side effects in the TV advertisement.

1 Sep 2008

Ranbaxy receives approval to manufacture Zolpidem tablets for insomnia

Ranbaxy Laboratories Limited (RLL), has announced that the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Zolpidem Tartrate Tablets, 5mg and 10mg.

27 Apr 2007

Mylan anounces FDA approval of Zolpidem Tartrate tablets

Mylan Laboratories has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Zolpidem Tartrate Tablets, 5 mg and 10 mg.

24 Apr 2007

FDA approves generic versions of Ambien

The U.S. Food and Drug Administration (FDA) today approved the first generic versions of Ambien (zolpidem tartrate) immediate-release tablets.

24 Apr 2007

Sedative-hypnotic drugs to get stronger warning labels

The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks.

14 Mar 2007

Prescription drug prices for U.S. residents ages 50 and older increased at about twice inflation rate

Manufacturers' prices for the 193 prescription drugs most commonly used by U.S. residents ages 50 and older increased at about twice the rate of inflation in 2006, according to an annual report released on Tuesday by AARP, Cox/Atlanta Journal-Constitution reports.

8 Mar 2007

FDA warns consumers about buying medications over the Internet

The Food and Drug Administration (FDA) in the United States has again warned consumers about buying medications over the Internet.

19 Feb 2007

Scientists spot mechanism behind promising new sleep drug

An experimental drug called gaboxadol may soon help millions of bleary-eyed insomniacs get to sleep, and a multi-center team of U.S. scientists believes they've pinpointed just how the drug works.

1 Nov 2006

Prices on medications most commonly used by older people rose 4.3% in first half of 2006

Manufacturer prices for the brand-name drugs most commonly used by individuals ages 50 and older increased by an average of 6.3% during the 12-month period ending in June, according to an AARP survey released on Tuesday, the Newark Star-Ledger reports.

22 Sep 2006

New sleep medication Ramelteon shows less potential to foster abuse and dependence

As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs.

27 Jun 2006

Strange behaviour blamed on sleeping pills

Reports of some very strange behavior by insomniacs taking a prescribed sleeping pill have been of concern and have raised safety questions about insomnia medications.

16 Mar 2006